Valencia

• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 Oligometastatic prostate cancer (OMPC)
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induc … Recruiting
  2024-514880-25-00 5 2024-06-27 Patients with cardiovascular alterations induced by cirrhosis, diabete
• An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with ad … Recruiting
  2023-504199-19-00 7 2024-06-26 Solid Tumours
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
• A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patient … Recruiting
  2023-508236-60-00 3 2024-06-13 Severe, Refractory Systemic Lupus Erythematosus
• Phase 2, randomised study of Radspherin® in patients with primary advanced epithelial cancer with peritoneal metastasis that are homologous … Recruiting
  2023-508497-28-00 4 2024-06-05 Carcinomatosis of peritoneal cavity
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting
  2023-508808-38-00 1 2024-05-29 Solid tumors
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION) Recruiting
  2023-505043-39-00 5 2024-05-24 Duchenne Muscular Dystrophy
• A study of ASP3082 in adults with advanced solid tumors Recruiting
  2022-501590-39-00 1 2024-05-22 Solid Tumor
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 10 2024-05-22 systemic sclerosis associated interstitial lung disease
• Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas Recruiting
  2023-509215-81-00 4 2024-05-22 Adult and young adult patients with diagnosis of advanced/metastatic s
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, th … Recruiting
  2023-509204-15-00 4 2024-05-17 Metastatic colorectal cancer
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• EFFECT OF THE USE OF DAPAGLIFLOZIN IN DIURESIS, NATRIURIESIS AND IN ULTRAFILTRATION AND PERITONEAL ELIMINATION OF SODIUM, IN PATIENTS WITH R … Recruiting
  2023-505571-78-00 6 2024-05-16 REFRACTORY HEART FAILURE
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting
  2024-511397-70-00 4 2024-05-06 metastatic renal cell carcinoma (mRCC)
• The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Recruiting
  2022-500319-38-00 4 2024-05-03 Paroxysmal supraventricular tachycardia (PSVT)

Showing 697–720 of 1,853 trials